Hannu Uusitalo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hannu Uusitalo has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Janika Nättinen
Department of Ophthalmology, Faculty of Medicine and Health Technology Tampere University Tampere Finland
6 shared publications - Ulla Aapola
Eye and Vision Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
6 shared publications - Jouko Saramies
South Karelia Social and Health Care District, Wellbeing services county of South Karelia, Finland
5 shared publications - Jaakko Tuomilehto
Public Health Promotion Unit, Finnish Institute for Health and Welfare, Helsinki, Finland
4 shared publications - Petri Purola
Department of Ophthalmology, Faculty of Medicine and Health Technology Tampere University Tampere Finland
4 shared publications - Anu Vaajanen
Eye and Vision Research SILK, Faculty of Medicine and Health Technology Tampere University Tampere Finland
3 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by Wiley in Acta Ophthalmologica
Usher syndrome‐related visual impairment in Finland: A 35‐year nationwide register‐based study (1985–2019)
Purpose: To investigate visual impairment (VI) associated with Usher syndrome (USH), a syndromic form of retinitis pigmentosa. Methods: This register‐based study used data from the Register of the Finnish Federation for Visual Impairment for persons registered with USH‐related VI from 1985 to 2019. Temporal trends in incidence, prevalence, recorded age at onset of VI, severity of registered VI, and sex distribution were analysed. Results: The mean annual incidence of USH–related VI remained relatively stable across decades ( p > 0.05), ranging from 0.19/100000 in 1985–1989 to 0.09/100000 in 2010–2019. In contrast, prevalence increased significantly over time ( p < 0.001), from 0.70/100000 in 1985–1989 to 2.84/100000 in 2010–2019. The mean recorded age at onset of VI remained relatively stable. A significant shift in severity distribution was observed ( p = 0.041), with fewer registrations classified as Near‐Total Blindness and Total Blindness. In the 2010s, the severity distribution of VI differed between women and men. Conclusion: As the first nationwide, long‐term register–based study of USH–related VI, this 35‐year analysis demonstrates stable incidence alongside increasing prevalence, with an observed redistribution of registered VI severity away from Near‐Total Blindness and Total Blindness. These findings reflect both the expected natural disease course and broader system‐level influences on registration patterns, underscoring the value of long‐term register data for monitoring rare disease epidemiology when interpreted in light of established clinical characteristics of USH, VI classification criteria, and the healthcare system context. Together, they support the need to refine approaches to VI classification, rehabilitation and public health planning for people with USH.
- 2 July 2026
- Published by Wiley in Acta Ophthalmologica
Open AccessUsher syndrome‐related visual impairment in Finland: A 35‐year nationwide register‐based study (1985–2019)
Purpose: To investigate visual impairment (VI) associated with Usher syndrome (USH), a syndromic form of retinitis pigmentosa. Methods: This register‐based study used data from the Register of the Finnish Federation for Visual Impairment for persons registered with USH‐related VI from 1985 to 2019. Temporal trends in incidence, prevalence, recorded age at onset of VI, severity of registered VI, and sex distribution were analysed. Results: The mean annual incidence of USH–related VI remained relatively stable across decades ( p > 0.05), ranging from 0.19/100000 in 1985–1989 to 0.09/100000 in 2010–2019. In contrast, prevalence increased significantly over time ( p < 0.001), from 0.70/100000 in 1985–1989 to 2.84/100000 in 2010–2019. The mean recorded age at onset of VI remained relatively stable. A significant shift in severity distribution was observed ( p = 0.041), with fewer registrations classified as Near‐Total Blindness and Total Blindness. In the 2010s, the severity distribution of VI differed between women and men. Conclusion: As the first nationwide, long‐term register–based study of USH–related VI, this 35‐year analysis demonstrates stable incidence alongside increasing prevalence, with an observed redistribution of registered VI severity away from Near‐Total Blindness and Total Blindness. These findings reflect both the expected natural disease course and broader system‐level influences on registration patterns, underscoring the value of long‐term register data for monitoring rare disease epidemiology when interpreted in light of established clinical characteristics of USH, VI classification criteria, and the healthcare system context. Together, they support the need to refine approaches to VI classification, rehabilitation and public health planning for people with USH.
- Open Access
- 27 January 2026
- Published by Wiley in Acta Ophthalmologica
- Vol. 104 (5) , 559-571
Direct and indirect costs associated with declining distance visual acuity: A nationwide longitudinal cost‐of‐illness study with 11‐year follow‐up
Purpose: To examine the direct and indirect costs associated with declining distance visual acuity (VA). Methods: A longitudinal approach was applied to a large, nationally representative sample with extensive data, including VA measured at two time points. The data of 3867 eligible participants aged 30 years or older at baseline were linked with national registers to estimate health care utilization from 1999 to 2013. A prevalence‐based bottom‐up approach was utilized to calculate the direct and indirect costs at the 2019 level. Data were adjusted for age, sex and incident comorbidities using generalized linear modelling (GLM). To estimate the cost‐of‐illness (COI), observed expenses among individuals whose VA declined during the follow‐up were compared to the counterfactual situation where VA had not declined, based on the regression analyses. Both individual and population‐level costs were reported. Results: The annual total direct health care costs per person were €976 for those with non‐declining VA and €1838 for those with declining VA (adjusted to match persons without decline in VA). The adjusted indirect costs were €14 579 and €22 631 for the working age subgroups, respectively. In counterfactual analysis, the annual COI associated with declining VA was estimated at €1166 from direct and €6411 from indirect cost sources. At the population level, the direct costs were €0.3 billion and the indirect costs, calculated for the working‐age population, were €0.4 billion annually. Conclusion: In total, 7.6% of the national direct health care costs were attributed to declining VA, highlighting the savings potential if the prevalence of declining VA could be reduced.
- 27 January 2026
- Published by Wiley in Acta Ophthalmologica
- Vol. 104 (5) , 559-571
Open AccessDirect and indirect costs associated with declining distance visual acuity: A nationwide longitudinal cost‐of‐illness study with 11‐year follow‐up
Purpose: To examine the direct and indirect costs associated with declining distance visual acuity (VA). Methods: A longitudinal approach was applied to a large, nationally representative sample with extensive data, including VA measured at two time points. The data of 3867 eligible participants aged 30 years or older at baseline were linked with national registers to estimate health care utilization from 1999 to 2013. A prevalence‐based bottom‐up approach was utilized to calculate the direct and indirect costs at the 2019 level. Data were adjusted for age, sex and incident comorbidities using generalized linear modelling (GLM). To estimate the cost‐of‐illness (COI), observed expenses among individuals whose VA declined during the follow‐up were compared to the counterfactual situation where VA had not declined, based on the regression analyses. Both individual and population‐level costs were reported. Results: The annual total direct health care costs per person were €976 for those with non‐declining VA and €1838 for those with declining VA (adjusted to match persons without decline in VA). The adjusted indirect costs were €14 579 and €22 631 for the working age subgroups, respectively. In counterfactual analysis, the annual COI associated with declining VA was estimated at €1166 from direct and €6411 from indirect cost sources. At the population level, the direct costs were €0.3 billion and the indirect costs, calculated for the working‐age population, were €0.4 billion annually. Conclusion: In total, 7.6% of the national direct health care costs were attributed to declining VA, highlighting the savings potential if the prevalence of declining VA could be reduced.
- Open Access
- 4 April 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (1) , 292-301
Altered tear fluid protein expression in persons with mild Alzheimer's disease in proteins involved in oxidative stress, protein synthesis, and energy metabolism
Background: Tear fluid (TF) is a protein-rich solution that reflects pathophysiological changes in Alzheimer's disease (AD). Objective: In this study, we examined whether TF proteins were differently expressed in persons with mild AD dementia compared to cognitively healthy controls (CO). Methods: We analyzed data from 53 study participants including 34 CO (mean age, 71 years; Mini-Mental State Examination [MMSE] score, 28.9 ± 1.4), and 19 patients with AD (Clinical Dementia Rating, 0.5–1; mean age, 72 years; MMSE score, 23.8 ± 2.8). All participants underwent cognitive testing, as well as neurological and ophthalmological examinations. TF was collected using Schirmer strips, and TF protein content was evaluated using mass spectrometry-based proteomics and label-free quantification. Results: We found that 16 proteins exhibited significantly upregulated expression in the AD group compared to the CO group ( p ≤ 0.05). These proteins were NP1L4, BBOX1, CYTC, RNAS4, PCD, RNT2, AL1A3, SYSC, TPIS, CLH1, PGAM1, EIF3L, 5NTC, HNRNPA2B1, PYGL, and ERO1α. No proteins were significantly downregulated in the AD group compared to the CO group. Conclusions: Our results support the hypothesis that TF is a potential source of biomarkers for AD. Part of those proteins with altered expression have previously linked to increased oxidative stress, changed protein synthesis, and disturbed regulation of energy metabolism related to AD or neurodegenerative disease. The present results indicate the value of continued investigation of TF proteins in AD.
- 4 April 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (1) , 292-301
Open AccessAltered tear fluid protein expression in persons with mild Alzheimer's disease in proteins involved in oxidative stress, protein synthesis, and energy metabolism
Background: Tear fluid (TF) is a protein-rich solution that reflects pathophysiological changes in Alzheimer's disease (AD). Objective: In this study, we examined whether TF proteins were differently expressed in persons with mild AD dementia compared to cognitively healthy controls (CO). Methods: We analyzed data from 53 study participants including 34 CO (mean age, 71 years; Mini-Mental State Examination [MMSE] score, 28.9 ± 1.4), and 19 patients with AD (Clinical Dementia Rating, 0.5–1; mean age, 72 years; MMSE score, 23.8 ± 2.8). All participants underwent cognitive testing, as well as neurological and ophthalmological examinations. TF was collected using Schirmer strips, and TF protein content was evaluated using mass spectrometry-based proteomics and label-free quantification. Results: We found that 16 proteins exhibited significantly upregulated expression in the AD group compared to the CO group ( p ≤ 0.05). These proteins were NP1L4, BBOX1, CYTC, RNAS4, PCD, RNT2, AL1A3, SYSC, TPIS, CLH1, PGAM1, EIF3L, 5NTC, HNRNPA2B1, PYGL, and ERO1α. No proteins were significantly downregulated in the AD group compared to the CO group. Conclusions: Our results support the hypothesis that TF is a potential source of biomarkers for AD. Part of those proteins with altered expression have previously linked to increased oxidative stress, changed protein synthesis, and disturbed regulation of energy metabolism related to AD or neurodegenerative disease. The present results indicate the value of continued investigation of TF proteins in AD.
- Open Access
- 28 January 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (5) , 1363-1376
Impact of signs and symptoms of dry eye disease on health-related quality of life: a cross-sectional population study among older adults
Purpose: To assess the relationship between quality of life (QoL) and ocular surface health within a Finnish population-based cohort. Methods: A cross-sectional study involved 601 individuals born between the years 1933–1956. Ocular surface health and dry eye disease (DED) were clinically evaluated using several diagnostic tests. Participants completed the Ocular Surface Disease Index (OSDI), QoL assessment with the 15D and Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), and the Beck’s Depression Inventory (BDI-II) questionnaires. Various statistical methods were employed to explore the associations between QoL, ocular surface health, and sex disparities. Results: DED had negative impact on QoL in all participants, and especially in women. Adjusted for comorbidities, DED doubled the odds of worse health-related QoL (15D: OR = 2.31 [95% CI: 1.24–4.31, p < 0.01]) and mental health (SF-36 MCS and BDI-II: OR = 2.08 [95% CI: 1.04–4.16, p < 0.05]). Noninvasive tear break-up time (NIBUT) correlated with all QoL scores. In women, the most significant clinical signs correlating with low QoL were NIBUT (15D: r = 0.20, p = 0.002; SF-36 MCS: r = 0.18, p = 0.026), and conjunctival staining (15D: r=-0.19, p = 0.004; BDI-II: r = 0.27, p < 0.001), whereas in men, blepharitis correlated with depression score (BDI-II: r = 0.20, p = 0.036). High OSDI was associated with worse QoL in women, but not in men. Conclusion: This first population-based study assessing general QoL data with objective clinical measures of DED indicated that among elderly population, both symptoms and signs of DED independently impacted different aspects of QoL. In addition, significant sex-differences in these associations were observed and should be considered both in research settings and when assessing and treating people with DED.
- 28 January 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (5) , 1363-1376
Open AccessImpact of signs and symptoms of dry eye disease on health-related quality of life: a cross-sectional population study among older adults
Purpose: To assess the relationship between quality of life (QoL) and ocular surface health within a Finnish population-based cohort. Methods: A cross-sectional study involved 601 individuals born between the years 1933–1956. Ocular surface health and dry eye disease (DED) were clinically evaluated using several diagnostic tests. Participants completed the Ocular Surface Disease Index (OSDI), QoL assessment with the 15D and Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), and the Beck’s Depression Inventory (BDI-II) questionnaires. Various statistical methods were employed to explore the associations between QoL, ocular surface health, and sex disparities. Results: DED had negative impact on QoL in all participants, and especially in women. Adjusted for comorbidities, DED doubled the odds of worse health-related QoL (15D: OR = 2.31 [95% CI: 1.24–4.31, p < 0.01]) and mental health (SF-36 MCS and BDI-II: OR = 2.08 [95% CI: 1.04–4.16, p < 0.05]). Noninvasive tear break-up time (NIBUT) correlated with all QoL scores. In women, the most significant clinical signs correlating with low QoL were NIBUT (15D: r = 0.20, p = 0.002; SF-36 MCS: r = 0.18, p = 0.026), and conjunctival staining (15D: r=-0.19, p = 0.004; BDI-II: r = 0.27, p < 0.001), whereas in men, blepharitis correlated with depression score (BDI-II: r = 0.20, p = 0.036). High OSDI was associated with worse QoL in women, but not in men. Conclusion: This first population-based study assessing general QoL data with objective clinical measures of DED indicated that among elderly population, both symptoms and signs of DED independently impacted different aspects of QoL. In addition, significant sex-differences in these associations were observed and should be considered both in research settings and when assessing and treating people with DED.
- Open Access
- 18 November 2024
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (1_suppl) , S42-S49
Tear fluid reflects the altered protein expressions of Alzheimer's disease patients in proteins involved in protein repair and clearance system or the regulation of cytoskeleton
Background: New biomarkers that improve diagnosis of Alzheimer's disease (AD) are warranted. Tear fluid (TF) containing variety of proteins that reflect pathophysiological changes of systemic diseases makes TF proteins potential biomarker candidates for AD. Objective: We investigated the expression levels of TF proteins in persons with mild AD and cognitively healthy controls (CO) to find out if altered proteins may link to the AD pathophysiology. Methods: We analyzed the data of the 53 study participants (34 COs, mean age 71 and Mini-Mental State Examination (MMSE) 28.9 ± 1.4 and 19 persons with AD, CDR 0.5–1, mean age 71 and MMSE 23.8 ± 2.8). All went through neurological status examination, cognitive tests, and ophthalmological examination. TF was collected using Schirmer strips. The TF protein content was evaluated via mass spectrometry-based proteomics and label-free quantification. Results: Eleven proteins having a role either in protein repair and clearance system, or regulation of cytoskeleton, showed altered expression in AD group compared to CO group. Seven of them were significantly ( p ≤ 0.05) upregulated (Sti1, Twf1, Myl6, Otub1, Pls1 and Caza1) or, downregulated (HSP90) in AD group. Conclusions: Altered expression of all these up- or downregulated proteins may be linked to AD pathophysiology. Thus, our results are encouraging for searching new biomarker candidates for AD. TF is potential biomarker candidate, because TF seems to reflect altered protein levels already in mild AD dementia.
- 18 November 2024
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (1_suppl) , S42-S49
Open AccessTear fluid reflects the altered protein expressions of Alzheimer's disease patients in proteins involved in protein repair and clearance system or the regulation of cytoskeleton
Background: New biomarkers that improve diagnosis of Alzheimer's disease (AD) are warranted. Tear fluid (TF) containing variety of proteins that reflect pathophysiological changes of systemic diseases makes TF proteins potential biomarker candidates for AD. Objective: We investigated the expression levels of TF proteins in persons with mild AD and cognitively healthy controls (CO) to find out if altered proteins may link to the AD pathophysiology. Methods: We analyzed the data of the 53 study participants (34 COs, mean age 71 and Mini-Mental State Examination (MMSE) 28.9 ± 1.4 and 19 persons with AD, CDR 0.5–1, mean age 71 and MMSE 23.8 ± 2.8). All went through neurological status examination, cognitive tests, and ophthalmological examination. TF was collected using Schirmer strips. The TF protein content was evaluated via mass spectrometry-based proteomics and label-free quantification. Results: Eleven proteins having a role either in protein repair and clearance system, or regulation of cytoskeleton, showed altered expression in AD group compared to CO group. Seven of them were significantly ( p ≤ 0.05) upregulated (Sti1, Twf1, Myl6, Otub1, Pls1 and Caza1) or, downregulated (HSP90) in AD group. Conclusions: Altered expression of all these up- or downregulated proteins may be linked to AD pathophysiology. Thus, our results are encouraging for searching new biomarker candidates for AD. TF is potential biomarker candidate, because TF seems to reflect altered protein levels already in mild AD dementia.
- 10 October 2024
- Published by Elsevier in Primary Care Diabetes
- Vol. 18 (6) , 618-623
Erectile dysfunction as a predictive indicator of asymptomatic diabetes and prediabetes
- 10 October 2024
- Published by Elsevier in Primary Care Diabetes
- Vol. 18 (6) , 618-623
Erectile dysfunction as a predictive indicator of asymptomatic diabetes and prediabetes
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Ophthalmology
- Vol. 2024 (1) , 6939920
Novel Human Induced Pluripotent Stem Cell‐Based Model for Retinal Pigment Epithelial Cells to Reveal Possible Disease Mechanisms for Macular Degeneration in Pseudoxanthoma Elasticum
Pseudoxanthoma elasticum (PXE) is a rare metabolic disease with autosomal recessive inheritance. The manifestation in PXE is represented by retinal complications, pseudoxanthomas of the skin folding areas, and arterial calcification. The retinal complications are caused by the calcification of Bruch’s membrane beneath retinal pigment epithelial cells (RPE) that can lead to retinal macular degeneration. The exact mechanism for the retinal pathophysiology is not known, and patients have variable symptoms and findings. Two induced pluripotent stem cell (hiPSC) lines from a patient carrying the common homozygous mutation c.3421C > T, p.Arg1141X in the ATP‐binding cassette transporter gene (ABCC6; OMIM264800) were established and fully characterized. Then, RPE cells were differentiated, and molecular and functional characterization was conducted as a comparison to healthy controls. Data demonstrated that PXE‐specific high‐quality hiPSC lines can be established from a skin biopsy regardless of the skin‐related disease phenotype and disease‐specific RPE differentiation is feasible. The molecular and functional assessment of the PXE‐specific RPE indicated increased pigmentation and reduced epithelial barrier functions as well as phagocytosis activity as compared to healthy controls. Although preliminary data, this indicates possible RPE‐dependent factors that might explain the individual vulnerability of the retinas for macular degeneration in PXE. Future validation of the novel findings with additional PXE patients will be important.
- 1 January 2024
- Published by Wiley in Journal of Ophthalmology
- Vol. 2024 (1) , 6939920
Open AccessNovel Human Induced Pluripotent Stem Cell‐Based Model for Retinal Pigment Epithelial Cells to Reveal Possible Disease Mechanisms for Macular Degeneration in Pseudoxanthoma Elasticum
Pseudoxanthoma elasticum (PXE) is a rare metabolic disease with autosomal recessive inheritance. The manifestation in PXE is represented by retinal complications, pseudoxanthomas of the skin folding areas, and arterial calcification. The retinal complications are caused by the calcification of Bruch’s membrane beneath retinal pigment epithelial cells (RPE) that can lead to retinal macular degeneration. The exact mechanism for the retinal pathophysiology is not known, and patients have variable symptoms and findings. Two induced pluripotent stem cell (hiPSC) lines from a patient carrying the common homozygous mutation c.3421C > T, p.Arg1141X in the ATP‐binding cassette transporter gene (ABCC6; OMIM264800) were established and fully characterized. Then, RPE cells were differentiated, and molecular and functional characterization was conducted as a comparison to healthy controls. Data demonstrated that PXE‐specific high‐quality hiPSC lines can be established from a skin biopsy regardless of the skin‐related disease phenotype and disease‐specific RPE differentiation is feasible. The molecular and functional assessment of the PXE‐specific RPE indicated increased pigmentation and reduced epithelial barrier functions as well as phagocytosis activity as compared to healthy controls. Although preliminary data, this indicates possible RPE‐dependent factors that might explain the individual vulnerability of the retinas for macular degeneration in PXE. Future validation of the novel findings with additional PXE patients will be important.
- Open Access
- 1 November 2023
- Published by Elsevier in Knowledge-Based Systems
- Vol. 283
A unified and practical user-centric framework for explainable artificial intelligence
- 1 November 2023
- Published by Elsevier in Knowledge-Based Systems
- Vol. 283
Open AccessA unified and practical user-centric framework for explainable artificial intelligence
- Open Access
- 26 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 7914
Proteomics Analysis of R-Ras Deficiency in Oxygen Induced Retinopathy
Small GTPase R-Ras regulates vascular permeability in angiogenesis. In the eye, abnormal angiogenesis and hyperpermeability are the leading causes of vision loss in several ischemic retinal diseases such as proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO), and retinopathy of prematurity (ROP). Oxygen-induced retinopathy (OIR) is the most widely used experimental model for these ischemic retinopathies. To shed more light on how the R-Ras regulates vascular permeability in pathological angiogenesis, we performed a comprehensive (>2900 proteins) characterization of OIR in R-Ras knockout (KO) and wild-type (WT) mice by sequential window acquisition of all theoretical mass spectra (SWATH-MS) proteomics. OIR and age-matched normoxic control retinas were collected at P13, P17, and P42 from R-Ras KO and WT mice and were subjected to SWATH-MS and data analysis. The most significant difference between the R-Ras KO and WT retinas was an accumulation of plasma proteins. The pathological vascular hyperpermeability during OIR in the R-Ras KO retina took place very early, P13. This led to simultaneous hypoxic cell injury/death (ferroptosis), glycolytic metabolism as well compensatory mechanisms to counter the pathological leakage from angiogenic blood vessels in the OIR retina of R-Ras deficient mice.
- 26 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 7914
Open AccessProteomics Analysis of R-Ras Deficiency in Oxygen Induced Retinopathy
Small GTPase R-Ras regulates vascular permeability in angiogenesis. In the eye, abnormal angiogenesis and hyperpermeability are the leading causes of vision loss in several ischemic retinal diseases such as proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO), and retinopathy of prematurity (ROP). Oxygen-induced retinopathy (OIR) is the most widely used experimental model for these ischemic retinopathies. To shed more light on how the R-Ras regulates vascular permeability in pathological angiogenesis, we performed a comprehensive (>2900 proteins) characterization of OIR in R-Ras knockout (KO) and wild-type (WT) mice by sequential window acquisition of all theoretical mass spectra (SWATH-MS) proteomics. OIR and age-matched normoxic control retinas were collected at P13, P17, and P42 from R-Ras KO and WT mice and were subjected to SWATH-MS and data analysis. The most significant difference between the R-Ras KO and WT retinas was an accumulation of plasma proteins. The pathological vascular hyperpermeability during OIR in the R-Ras KO retina took place very early, P13. This led to simultaneous hypoxic cell injury/death (ferroptosis), glycolytic metabolism as well compensatory mechanisms to counter the pathological leakage from angiogenic blood vessels in the OIR retina of R-Ras deficient mice.
- Open Access
- 1 August 2022
- Published by Wiley in Acta Ophthalmologica
- Vol. 101 (1) , 57-64
Visual impairment due to age‐related macular degeneration during 40 years in Finland and the impact of novel therapies
Purpose: To evaluate the changes in visual impairment (VI) due to age‐related macular degeneration (AMD) during the past 40 years and the impact of novel therapies at population level.Methods: In this nationwide register‐based study, we assessed the incidence, prevalence, severity, and onset age of VI due to AMD based on the Finnish Register of Visual Impairment data from 1980 to 2019. Our data included 30 016 visually impaired persons with AMD as the main diagnosis for VI. The number of persons treated with intravitreal injections in Finland was obtained from hospital data kept by the Finnish Institute for Health and Welfare.Results: Between the 1980s and the 2010s, the incidence of reported VI doubled; however, this increase has stagnated in the 2010s. Since 2012, the prevalence of reported VI has decreased. The number of patients treated with intravitreal injections showed a 40‐fold increase during 2005–2019. The severity of reported VI has decreased whereas the mean age at the onset of reported VI has increased during the 40 years. The age‐adjusted incidence and prevalence of reported VI were significantly higher in females in comparison to males in all decades.Conclusion: Increase in the incidence and prevalence of VI due to AMD in the past decades has stagnated and shifted to older age in the 2010s when therapies for exudative class became commonly available. Furthermore, the prognosis of VI has improved during the past 40 years. These positive trends are likely contributable to improved diagnostic tools, earlier diagnoses, and new therapy options.
- 1 August 2022
- Published by Wiley in Acta Ophthalmologica
- Vol. 101 (1) , 57-64
Open AccessVisual impairment due to age‐related macular degeneration during 40 years in Finland and the impact of novel therapies
Purpose: To evaluate the changes in visual impairment (VI) due to age‐related macular degeneration (AMD) during the past 40 years and the impact of novel therapies at population level.Methods: In this nationwide register‐based study, we assessed the incidence, prevalence, severity, and onset age of VI due to AMD based on the Finnish Register of Visual Impairment data from 1980 to 2019. Our data included 30 016 visually impaired persons with AMD as the main diagnosis for VI. The number of persons treated with intravitreal injections in Finland was obtained from hospital data kept by the Finnish Institute for Health and Welfare.Results: Between the 1980s and the 2010s, the incidence of reported VI doubled; however, this increase has stagnated in the 2010s. Since 2012, the prevalence of reported VI has decreased. The number of patients treated with intravitreal injections showed a 40‐fold increase during 2005–2019. The severity of reported VI has decreased whereas the mean age at the onset of reported VI has increased during the 40 years. The age‐adjusted incidence and prevalence of reported VI were significantly higher in females in comparison to males in all decades.Conclusion: Increase in the incidence and prevalence of VI due to AMD in the past decades has stagnated and shifted to older age in the 2010s when therapies for exudative class became commonly available. Furthermore, the prognosis of VI has improved during the past 40 years. These positive trends are likely contributable to improved diagnostic tools, earlier diagnoses, and new therapy options.